Jeff Aronin is an entrepreneur who focuses on the healthcare industry. His current business is Paragon Biosciences which seeks to provide drug therapies for rare diseases. These types of diseases affect less than 200,000 people and so often little research has been done on them. He is a graduate of Northern Illinois University which is where he earned his bachelor’s degree. Later on he attended DePaul University, earning his masters of business administration.
The first company Jeff Aronin founded was Ovation Pharmaceuticals, another firm in the healthcare industry. He built Ovation into a company with a valuation of $900 million. He sold this company in 2009 to Lundbeck which is a firm based in the Netherlands. he stayed with this company as its chief executive officer after the sell and guided it through it transition to being owned by this other company.
At Paragon Biosciences, Jeff Aronin and his team first seek to build an understanding of a particular illness. They then see if it can be addressed through groundbreaking science. If so they establish a startup which focuses on this one disease. One rare disease that Jeff Aronin has been instrumental in developing a treatment for is a very uncommon version of epilepsy. People with this form of epilepsy can experience up to hundreds of seizures a day. His company developed a drug which could successfully treat this form of epilepsy in combination with other prescription drugs and therapy.
Another disease Jeff Aronin has helped create a therapy for is one called porphyria. One person who had this rare disease, Desiree Lyon, said she would have pains in her stomach that felt like a thousand flaming swords were being shoved into her. She had to go into intensive care 30 times and twice she went into total paralysis.
Over time Lyon went to different doctors who didn’t diagnose what she was suffering from. It was eventually diagnosed as porphyria and she was prescribed a medicine to treat it. She says she partnered with Jeff Aronin so that no other person had to go through what she had in regards to this disease.